吉西他滨加奥沙利铂治疗晚期胃肠道肿瘤31例近期疗效  

The Short-term Efficacy of Gemcitabine Combined with Oxaliplatin in Treat-ment of 31 Cases with Advanced Gastrointestinal Cancer

作　　者：裘友好[1] 钟海均[1] 方美玉[1] 郑亚兵[1] 

机构地区：[1]浙江省肿瘤医院,浙江杭州310004

出　　处：《肿瘤学杂志》2004年第3期175-176,共2页Journal of Chinese Oncology

摘　　要：[目的]观察吉西他滨(健择)联合奥沙利铂(艾恒)治疗晚期胃肠道肿瘤的疗效和不良反应。[方法]入组31例均为复治晚期病人,胃癌14例,肠癌17例。化疗为吉西他滨1000mg/m2,静脉滴注30min,第1、8天;奥沙利铂130mg/m2,静脉滴注,第1天,每3周重复,治疗2个周期以上评价疗效。[结果]31例中CR1例,PR7例,SD15例,PD8例,有效率(CR+PR)25.8%(8/31),其中胃癌PR2例,有效率14.3%(2/14);肠癌CR1例,PR5例,有效率35.3%(6/17),临床受益率74.2%,胃癌和肠癌的临床受益率分别为71.4%和76.5%。不良反应主要为骨髓抑制和外周神经感觉异常。[结论]吉西他滨加奥沙利铂方案二线治疗晚期胃肠道肿瘤有一定疗效,对肠癌的治疗效果好于胃癌,毒副反应温和可耐受,有较好的临床受益。To investigate the efficacy and toxicities of Gemcitabine combined with Oxaliplatin in treating advanced gastrointestinal cancer. Thirty-one cases of ex-treated recurrent or metastatic gastrointestinal cancer were enrolled, including gastric and colonrectal cancer (14 and 17 cases). Gemcitabine was infused 1000mg/m2 for 30 minutes d1 and d8, Oxaliplatin was infused 130mg/m2 d1. The regimen was repeated every 3 weeks. After 2 cycles of treatment, the assessment was done. Thirty-one cases were evaluable for efficacy, CR, 1 case; PR, 7 cases; SD, 15 cases; PD, 8 cases. The overall response rate was 25.8%(8/31), with 14.3% in gastric cancer and 35.3% in colonrectal cancer. The clinical benefit rate was 74.2%, with 71.4% in gastric cancer and 76.5% in colonrectal cancer. The main side-effects were bone marrow suppression and neurosensory toxicity. [Conclusions] Gemcitabine combined with Oxaliplatin regimen is effective in treating advanced gastrointestinal cancer as second line treatment. The side-effects are mild. The efficacy of the regimen for gastric cancer is superior to colonrectal cancer.

关 键 词：胃肠肿瘤 吉西他滨 奥沙利铂 药物疗法 

分 类 号：R735.2[医药卫生—肿瘤] R735.3[医药卫生—临床医学]